简介：

简介：AIMTo评估联合反脉管的endothelial生长的功效和安全因素(VEGF)代理人，口头的glucocorticoid，和为有斑点的浮肿的激光光致疑结治疗(我)对.METHODSThis学习包括了的网膜的静脉吸藏(RVO)第二等16个病人与的16只眼睛联系RVO我。病人们开始与口头的泼尼松和一个intravitrealanti-VEGF代理人被对待。二个星期以后，病人们经历了标准激光光致疑结。改正最好的视觉尖酸(BCVA)，中央网膜的厚度(CRT)，和网膜的容器氧化在收到的12mo.RESULTSPatients上被检验1.43

简介：无

简介：Inthisreviewpaper,weintroduceaself-phasecontrolledstimulatedBrillouinscatteringphaseconjugatemirror(SCSBS-PCM)andtheKumganglaser.TheSC-SBS-PCMwasproposedanddemonstrateditssuccessattheacademiclowpowerlevel,~100mJ@10Hz.TheKumganglaserisunderdevelopmenttoverifywhethertheSC-SBS-PCMisoperableatthekWlevel.Itisa4kWbeamcombinationlasercombiningfour1kWbeamsusingtheSC-SBS-PCM.IftheKumganglaserfunctionssuccessfully,itwillbethemostimportantsteptowardsaDreamlaser,ahypotheticallaserwithunlimitedpowerandahighrepetitionrate.

简介：

简介：

简介：Objective:Therecurrenceorprogressionunderendocrinetherapyinhormonereceptor-positive(HR+)advancedbreastcancer(ABC)remainedacriticalclinicalchallenge.Chidamideisanoralsubtype-selectivehistonedeacetylase(HDAC)inhibitorwithmultiplefunctionsintumorgrowthinhibitionandmicroenvironmentmodulationviaepigeneticreprogramming.Thepurposeofthisstudywastoevaluatethesafety,pharmacokinetics(PK),andpreliminaryefficacyofchidamideincombinationwithexemestaneinHR+ABCpatients.Methods:EligiblepatientswerepostmenopausalwomenwithHR+ABCrecurrentorprogressedtoatleastoneendocrinetherapy.Bloodsampleswereobtainedintherun-inperiodandthefirstdayofcombinationtreatmentforPKanalysis.Incombinationtreatment,patientsweregivenexemestane25mgdailyandchidamide30mgtwiceaweek(BIW)untilprogressionofdiseaseorintolerabletoxicities.Atreatmentcyclewasdefinedas4weeks.Safety,PKparameters,andpreliminaryefficacywereevaluated.Results:Atotalof20patientswereenrolledbetweenJulyandDecember,2015.Themediannumberoftreatmentscyclewas5.2(20.8weeks)with2patientsstillontreatmentatthedatacut-offdateofOctober,2017.Thetreatment-relatedadverseevents(AE)≥grade3inmorethan2patientswereneutropenia(35%),thrombocytopenia(30%),andleucopenia(20%).Theplasmaexposureofexemestanewasconsistentinthepresenceorabsenceofchidamide.Aslightincreaseinchidamideexposurewasnotedinthepresenceofexemestane,probablyduetotheinter-andintra-patientvariations.Thebestresponsein16evaluablepatientswasassessedbyResponseEvaluationCriteriainSolidTumors(RECIST),including4patientswithpartialresponse,10patientswithstabledisease.Themedianprogression-freesurvival(PFS)was7.6months.Conclusions:ThecombinationofchidamidewithexemestanewasgenerallywelltoleratedwithpromisingpreliminaryefficacyinHR+ABCpatients.Theoverallresultsfromthisstudyencouragefurtherpivotaltrialinthispatie

简介：BackgroundNon-ST-segmentelevationacutecoronarysyndrome(NSTE-ACS)isanacuteheartdiseasecausedbyincompleteocclusionofrelatedcoronaryarterieswithunstableatheroscleroticplaques.LeadaVRSTsegmentelevationandcTnIpositivearecloselycorrelatedtotheprognosisofNSTE-ACSpatients.However,therearefewstudiesapplyingthetwopredictorstoearlyriskstratificationinNSTE-ACSpatients.MethodTwohundredandfivecasesofNSTE-ACSpatientsfollowedupfor6monthsafterdischargewerereviewed.Allpatientsweredividedintofourgroups:GroupA-cTnInegativecombinedwithaVR-non-ST-segmentelevationgroup(100cases);GroupB-cTnInegativecombinedwithaVR-ST-segmentelevationgroup(31cases);GroupC-cTnIpositivecombinedwithaVR-non-ST-segmentelevationgroup(43cases);GroupD-cTnIpositivecombinedwithaVR-ST-segmentelevationgroup(31cases).Therewasnosignificantdifferenceingender,age,oldmyocardialinfarction,previousPCIhistory,hypertension,anddiabetesbetweenaVR-STelevationgroupandnoaVR-STelevationgroup.Themorbidityofleftmainorthree-vesselcoronaryarterydiseaseaswellasadversecardiovasculareventsinthefourgroupswereobservedandanalyzed.Results(i)Themorbidityofleftmainorthree-vesselcoronaryarterydiseasewashighestinGroupD(87.1%),andwasmarkedlyhigherinGroupB(41.9%)thanthatinGroupA(7%)orGroupC(9.3%);(ii)TheincidenceofadversecardiovasculareventswashighestinGroupD(77.4%),andwasmuchhigherinB(35.5%)ascomparedwiththattinGroupA(1%)orgroupC(7%).ConclusionElectrocardiographicleadaVRST-segmentelevationcombinedwithcTnIpositivehasanimportantclinicalvalueinpredictingtheprognosisofthepatientswithNSTE-ACS.

简介：AIM:Tocomparetheefficacyandsafetyofcombinationofranibizumabwithphotodynamictherapy(PDT)vsranibizumabmonotherapyinthetreatmentofage-relatedmaculardegeneration(AMD).METHODS:TheCochraneCentralRegisterofControlledTrials(CENTRAL)intheCochraneLibrary,Pubmed,andEmbaseweresearched.Therewerenolanguageordatarestrictionsinthesearchfortrials.Onlyrandomizedcontrolledtrials(RCTs)wereincluded.MethodologicalqualityoftheliteratureswasevaluatedaccordingtotheJadadScore.RevMan5.2.6softwarewasusedtodothemeta-analysis.RESULTS:Sevenstudieswereincludedinoursystematicreview,amongwhichfourofthemwereincludedinquantitativeanalysis.Theresultshowsthattheranibizumabmonotherapygrouphadabettermeanbestcorrectedvisualacuity(BCVA)changevsbaselineatmonth12comparedwiththatofthecombinationtreatmentgroup,andthestatisticaldifferencewassignificant(WMD,-2.61;95%CI,-5.08to-0.13;P=0.04).However,aftertheremovalofonestudy,thedifferencebetweenthetwogroupsshowednosignificantdifference(WMD,-2.29;95%CI,-4.81to0.23;P=0.07).Meanwhile,nosignificantcentralretinalthickness(CRT)reductionwasfoundinthecombinationtreatmentgroupandtheranibizumabmonotherapygroupat12monthsfollow-up.Nevertheless,thecombinationgrouptendedtohaveagreaterreductioninCRT(WMD,-4.13μm;95%CI,-25.88to17.63,P=0.71).Theproportionofpatientsgainingmorethan3linesatmonth12intheranibizumabgroupwashigherthaninthecombinationgroupandtherewasasignificantdifference(RR,0.72;95%CI,0.54to0.95;P=0.02).Whereastherewasnosignificantdifferencefortheproportionofpatientsgainingmorethan0lineatmonth12betweenthetwogroups(RR,0.93;95%CI,0.76to1.15;P=0.52).Thegeneraltendencyshowsareductioninranibizumabretreatmentnumberinthecombinationtreatmentgroupcomparedwiththeranibizumabmonotherapygroup.Asmajoradverseevents,thedifferencesinthenumberofeyepain,endophthalmitis,hypertensionandarterialt

简介：Harmonic,subharmonic,superharmonic,simultaneoussub/superharmonic,andcombinationresonancesoftheadditivetypeofself-excitedtwocoupled-secondordersystemstomulti-frequencyexcitationareinvestigated.Thetheoreticalresultsareobtainedbythemultiple-scalesmethod.Thesteadystateamplitudesforeachresonanceareplotted,showingtheinfluenceofthedifferentparameters.Analysisforeachfigureisgiven.Approximatesolutioncorrespondingtoeachtypeofresonanceisdetermined.Stabilityanalysesarecarriedoutforeachcase.

简介：Thebioavailabilityofdocosahexaenoicacid(DHA)andeicosapentaenoicacid(EPA)dependsontheirchemicalforms.Thisstudyinvestigatedthelong-termeffectsofDHA-boundtriglyceride(TG-DHA),DHA-boundphospholipid(PL-DHA),andthecombinationofTG-DHAandeggyolkphospholipid(Egg-PL)onlipidmetabolisminmicefedwithahigh-fatdiet(fatlevelsof22.5%).MaleC57BL/6Jmicewerefedwithdifferentformulationscontaining0.5%DHA,includingTG-DHA,PL-DHA,andthecombinationofTG-DHAandEgg-PL,for6weeks.Serum,hepatic,andcerebrallipidconcentrationsandthefattyacidcompositionsoftheliverandbrainweredetermined.Theconcentrationsofserumtotaltriglyceride(TG),totalcholesterol(TC),high-densitylipoproteincholesterol(HDL-c),andhepaticTGinthePL-DHAgroupandthecombinationgroupweresignificantlylowerthanthoseinthehigh-fat(HF)group(P<0.05).Atherogenicindex(AI)ofthePL-DHAgroupwassignificantlylowerthanthatofthecombinationgroup(P<0.05).HepaticTClevelinthecombinationgroupwassignificantlylowerthanthatintheHFgroup(P<0.05),butnosignificantdifferencewasobservedbetweenthecombinationgroupandthePL-DHAgroup.BoththePL-DHAandthecombinationgroupsshowedsignificantlyincreasedDHAlevelsinthelivercomparedwiththeHFgroup(P<0.05).However,therewerenoobviousincreasesinthecerebralDHAlevelsinallDHAdietgroups.TheseresultssuggestthatPL-DHAwassuperiortothecombinationofTG-DHAandEgg-PLindecreasingtheAI.Long-termdietarysupplementationwithlowamountofDHA(0.5%)mayimprovehepaticDHAlevels,althoughcerebralDHAlevelsmaynotbeenhanced.

简介：AbstractIn recent years, immune checkpoint inhibitors (ICIs) have made breakthroughs in the field of lung cancer and have become a focal point for research. Programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor monotherapy was the first to break the treatment pattern for non-small cell lung cancer (NSCLC). However, owing to the limited benefit of ICI monotherapy at the population level and its hyper-progressive phenomenon, it may not meet clinical needs. To expand the beneficial range of immunotherapy and improve its efficacy, several research strategies have adopted the use of combination immunotherapy. At present, multiple strategies, such as PD-1/PD-L1 inhibitors combined with chemotherapy, anti-angiogenic therapy, cytotoxic T-lymphocyte-associated protein 4 inhibitors, and radiotherapy, as well as combined treatment with new target drugs, have been evaluated for clinical practice. To further understand the current status and future development direction of immunotherapy, herein, we review the recent progress of ICI combination therapies for NSCLC.

简介：可观的证据显示那种类型1个T助手(Th1)-并且当时，调停Th17的有免疫力的回答支持动脉粥样硬化患者匾的形成那CD4+CD25+规章的T房间(Tregs)有的Foxp3+保护的效果。然而，因为令人满意的匾破裂模型的缺乏，在匾破裂遗体的多样的CD4+淋巴细胞子集的功能糟糕理解。这里，我们在颈动脉动脉上用一本高脂肪的食谱和领子放置建立了动脉粥样硬化患者匾破裂的一个鼠科的模型，并且在apolipoprotein电子大美人与lipopolysaccharide，phenylephrine注射和寒冷的联合由短期的刺激触发了匾破裂(ApoE−/−)老鼠。我们由PCR，流动cytometry，ELISA和immunohistochemistry调查了在Th1房间，Th17房间和Tregs和匾破裂之间的协会。总共，75%；(18/24)脆弱的匾，而是没有稳定的匾，显示出的破裂特征。Th17房间的比例在处理以后在splenocytes之中被增加，但是在Th1房间和Tregs的层次的变化不与破裂有关。而且，处理在浆液并且在匾破裂的区域导致了interleukin-17(IL-17)的高水平。在vitro，IL-17增加了apoptosis的水平，与匾破裂联系的一个主要因素，在有教养的鼠科的脉管的光滑的肌肉房间。Th17房间和IL-17可以涉及短期的刺激在ApoE−/−老鼠。

简介：客观：为了探索病理和临床的反应率的变化，为非小的房间肺癌症与MVP政体由neoadjuvant化疗对待。方法：这是在有阶段I-IIIa的病人的使随机化的研究。在他们之中，46个病人在neoadjuvant注册了1鈥对待的化疗吗？功课MVP政体。MMC被给6mg/M2由静脉内(I.V)day1上的注入，VDS2.5鈥吗？day1,8或day15上的mg/M2I.V，day1上的DDP90mg/M2I.V。治疗每28天被再循环。评估与的临床的RR标准。所有外科的样品与病理被分类。结果：在2功课化疗的全面反应率在1堂功课比那好(P<0.01)。有病理等级的病人的数字我在2功课化疗的鈥揑I比那高嗨1堂功课(P<0.01)。但是RR不能完全翻译了成病理等级我鈥揑I。病理等级我鈥揑I仔细与肿瘤参与(T)被联系(P<0.01)然而并非与地区性的淋巴节点转移(N)密切相关。和PCR使用RR判定化疗反应是合理的。NR病人不能作为化疗失败是问候。不服务毒性和外科的死亡被观察。结论：MVP政体是为I-IIIaNSCLC的有效neoadjuvant治疗政体。

简介：

简介：

简介：RecombinanthumanGABAAreceptorswereinvestigatedinvitrobycoexpressionofcDNAscodingforα1,β2andγ2subunitsinthebaculovirus/Sf-9insectcellsystem,Asingleaminoacidexchangeα1(asparaticacid151toasparaginorα1(threonine149toglutamine)intheN-terminal,extracellularpartoftheα1subunitinducedabout10folddecreaseinanantagonistpitrazepineaffinity.OtherGABAAreceptorligandshadlittledifferenceintheiraffinity.Itwaslikelythat151and149aminoacidresidueswereessentialforthebindingaffinityandefficacyofpitrazepinetoGABAAreceptorcombinationscontainiαααααααααnganα1subunit.